JP2005526026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526026A5 JP2005526026A5 JP2003565982A JP2003565982A JP2005526026A5 JP 2005526026 A5 JP2005526026 A5 JP 2005526026A5 JP 2003565982 A JP2003565982 A JP 2003565982A JP 2003565982 A JP2003565982 A JP 2003565982A JP 2005526026 A5 JP2005526026 A5 JP 2005526026A5
- Authority
- JP
- Japan
- Prior art keywords
- growth factor
- receptor
- compound
- factor receptor
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims description 39
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 27
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims 14
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims 14
- 108091008794 FGF receptors Proteins 0.000 claims 10
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 10
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 claims 10
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 10
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 10
- 108091008606 PDGF receptors Proteins 0.000 claims 10
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 10
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 10
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 10
- 108091008605 VEGF receptors Proteins 0.000 claims 10
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 10
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 6
- 102000003746 Insulin Receptor Human genes 0.000 claims 5
- 108010001127 Insulin Receptor Proteins 0.000 claims 5
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 claims 5
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000013270 controlled release Methods 0.000 description 4
- -1 3.3 g Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- YTHJCZRFJGXPTL-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1[N+]([O-])=O YTHJCZRFJGXPTL-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35415302P | 2002-02-06 | 2002-02-06 | |
| PCT/IL2003/000094 WO2003066608A1 (en) | 2002-02-06 | 2003-02-05 | Catechol bioisosteres |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526026A JP2005526026A (ja) | 2005-09-02 |
| JP2005526026A5 true JP2005526026A5 (https=) | 2006-03-30 |
Family
ID=27734325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565982A Abandoned JP2005526026A (ja) | 2002-02-06 | 2003-02-05 | カテコール生物学的等価体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050143430A1 (https=) |
| EP (1) | EP1472237A4 (https=) |
| JP (1) | JP2005526026A (https=) |
| AU (1) | AU2003206109A1 (https=) |
| WO (1) | WO2003066608A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01309B (me) * | 2004-08-26 | 2013-12-20 | Pfizer | Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza |
| WO2006087718A1 (en) * | 2005-02-17 | 2006-08-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Extension of lifespan with drugs |
| CN103360338B (zh) * | 2013-07-30 | 2015-04-01 | 中国科学院新疆理化技术研究所 | 一种查尔酮苯并噻唑酰胺类衍生物的制备方法和用途 |
| CN104230755A (zh) * | 2014-09-03 | 2014-12-24 | 无锡艾德美特生物科技有限公司 | 一类查耳酮类衍生物及其制备和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2244507A1 (en) * | 1973-06-26 | 1975-04-18 | Inst Nat Sante Rech Med | Chalcones and analogues - analgesics having low toxicity |
| FR2643634A1 (fr) * | 1989-02-28 | 1990-08-31 | Adir | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| JPH05331129A (ja) * | 1990-08-30 | 1993-12-14 | Suntory Ltd | カフェー酸誘導体及びそれを含む医薬組成物 |
| EP0567090B1 (en) * | 1992-04-24 | 2000-07-26 | Takeda Chemical Industries, Ltd. | Benzoxazepine derivatives as cholinesterase inhibitors |
| IL159270A0 (en) * | 2001-06-14 | 2004-06-01 | Yissum Res Dev Co | Non-myeloablative tolerogenic treatment with tyrphostins |
-
2003
- 2003-02-05 JP JP2003565982A patent/JP2005526026A/ja not_active Abandoned
- 2003-02-05 WO PCT/IL2003/000094 patent/WO2003066608A1/en not_active Ceased
- 2003-02-05 EP EP03702993A patent/EP1472237A4/en not_active Withdrawn
- 2003-02-05 AU AU2003206109A patent/AU2003206109A1/en not_active Abandoned
-
2004
- 2004-08-05 US US10/914,010 patent/US20050143430A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009009501A4 (en) | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | |
| JP2007529421A5 (https=) | ||
| JP2009504763A5 (https=) | ||
| JP2009537461A5 (https=) | ||
| RU2018103944A (ru) | Производные этинила как модуляторы метаботропного рецептора глутамата | |
| JP2005002129A5 (https=) | ||
| EP3759083B1 (en) | 2,4-diaminoquinazoline derivatives and use thereof in the treatment of virus infections, cancer or allergies | |
| JP2004514663A5 (https=) | ||
| JP2004528334A5 (https=) | ||
| JP2004506041A5 (https=) | ||
| JP2015536997A5 (https=) | ||
| EP2919779A1 (en) | Cannabinoid receptor mediating compounds | |
| EP2144887A1 (en) | Dosages and methods for the treatment of cancer | |
| JP2014504648A5 (https=) | ||
| RU2003130644A (ru) | Производные ркарболина и их фармацевтическое применение против дипрессии и страха | |
| CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| JP2005526026A5 (https=) | ||
| CN1424313A (zh) | 川芎醇酯类衍生物及其制备方法和含有川芎醇酯类衍生物的药物组合物与应用 | |
| CN113214230B (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| CN109422664B (zh) | 一类干扰素调节剂及其制备方法和用途 | |
| CA2504496A1 (en) | N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor | |
| JP2019501971A5 (https=) | ||
| JP6542799B2 (ja) | 新規ｐｅｇ誘導体 | |
| CN102274164B (zh) | 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂 | |
| EP1872798B1 (en) | Intestinal absorptive anti-tumor agent |